Longitudinal Study for Relapsing Polychondritis
Launched by UNIVERSITY OF PENNSYLVANIA · Jun 2, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, known as the Longitudinal Study for Relapsing Polychondritis, is focused on understanding a rare condition called relapsing polychondritis (RP). This disease causes repeated inflammation of cartilage in various parts of the body, like the ears, nose, and joints. Sometimes, it can also affect the eyes and skin. The researchers want to learn more about how this condition develops and affects patients over time.
If you or someone you know has been diagnosed with relapsing polychondritis, you may be eligible to participate in this study. The main requirement is having a confirmed diagnosis of RP. The trial is currently looking for participants of all ages and genders. Those who join can expect to share their experiences and health information, which will help researchers better understand this condition. It's important to note that individuals who cannot provide consent or are minors will not be eligible to participate. This study aims to improve knowledge about RP and possibly lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Any subject considered to have a diagnosis of relapsing polychondritis according to the investigator.
- Exclusion Criteria:
- • 1. Inability to provide consent, or in the case of minors, assent.
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Peter Merkel, MD, MPH
Study Director
University of Pennsylvania
Shubhasree Banerjee, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials